Production, quality control, and bio-distribution of 141Ce-EDTMP as a potential bone pain palliation agent

Background: The purpose of this present was to introduce 141Ce-EDTMP as a novel potential pain palliative agent to patients suffering from disseminated skeletal metastases and diagnostic imaging radioisotope as well. Cerium-141 [T1/2=32.501 days, Eβ (max)=0.580 (29.8%) and 0.435(70.2%) MeV, Eγ=145.44 (48.2%) keV] possesses suitable properties for use in palliative therapy of bone metastases.Methods: Ethylene diamine tetramethylene phosphonic acid (EDTMP) was synthesized and radiolabeled with 141Ce. Complexation parameters were optimized to achieve maximum yields (> 99%). The radiochemical purity of 141Ce-EDTMP was evaluated by radio-thin layer chromatography. The stability of the complex that monitored for one week at room temperature was > 99%. Biodistribution of the complexes carried out in wild-type rats.Results: The images showed high uptake of complex in bone after 72h. The percentage injected dose per gram of tissue (%ID/g) for each organ was calculated. The blood clearance was rapid.Conclusion: The properties of produced 141Ce-EDTMP suggest a new agent to overcome metastatic bone pains.

Keywords:

Cerium-141 , Bone pain palliative , EDTMP , Radiopharmaceutical , Therapy